by Cal Strode | Nov 2, 2026
Back in August 2016, Signals celebrated ten years of induced pluripotent stem cells (iPSCs) by hosting its first-ever blog carnival, in which contributors each wrote posts answering the same question: With useful treatments for diseases like heart failure and diabetes...
by Stacey Johnson | Aug 7, 2026
What are peptides and why are they all over traditional and social media? Peptides are chains of molecules called amino acids that link together; they are smaller versions of proteins. Thousands of naturally occurring peptides have been identified in the human body....
by Stacey Johnson | Jul 23, 2026
“Regulatory approval does not translate to dollars for a company, nor does it lead to patients being treated. Without reimbursement, all of the efforts of translation and development are lost.” My former colleague, Mark Curtis, wrote these words back when he blogged...
by Sanat Khanna | May 12, 2026
Cell therapy manufacturing generates large volumes of process data – from sensors, bioreactors, quality controls and genomic assays. In many facilities, much of that data are collected for regulatory compliance rather than for process improvement – a pattern that...
by Lyla El-Fayomi | Mar 12, 2026
Somehow we are already into March, and spring – at least in some places – feels close by. To catch you up, I’ve put together a recap of some of the research that scientists were buzzing about in the field of regenerative medicine from 2025; I cover the good, the bad,...
by Laya Kiani | Feb 12, 2026
In 2025, cell and gene therapy (CGT) showed growing clinical familiarity even as access and reimbursement challenges persisted. Providers and payers increasingly trusted and valued CGTs, supporting the continued expansion of late-stage programs. However, startup...
Comments